Prognostic Impact of Sequential Measurable Residual Disease and KIT Variant Status in Pediatric Core-Binding Factor Acute Myeloid Leukemia: A Retrospective Multicenter Study of the Taiwan Pediatric Oncology Group.
Checking blood cancer levels multiple times during treatment—not just once—better predicts which children will relapse, allowing doctors to tailor intensity and potentially improve outcomes.
This Taiwan Pediatric Oncology Group multicenter retrospective study of 112 children with CBF-AML demonstrates that sequential MRD monitoring at multiple timepoints—particularly at end of second consolidation and end of consolidation—provides stronger prognostic discrimination than single-timepoint MRD, with specific log-reduction thresholds defined for both RUNX1::RUNX1T1 and CBFB::MYH11 subtypes. Integration of KIT D816 variant status adds independent prognostic value, as patients with both <4-log MRD reduction and KIT D816 at EOC had extremely poor survival, while achieving ≥4-log MRD clearance rescued outcomes regardless of KIT status.
What the study was
- Study design
- Retrospective multicenter observational study
- Population
- 112 pediatric patients with core-binding factor AML (RUNX1::RUNX1T1 and CBFB::MYH11)
- Sample size
- 112
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Annals of laboratory medicine
Why it surfaced
Multicenter (7 institutions) pediatric AML study (n=112) providing actionable sequential MRD + KIT variant thresholds that directly guide risk stratification and treatment intensification decisions; clinically immediately translatable to pediatric CBF-AML management.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.